Results 131 to 140 of about 21,298 (206)

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial. [PDF]

Breast Cancer Res Treat
Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, Amann N, Cieslik JP, Dannehl D, Deutsch TM, Dimpfl M, Ehlert M, Eichstädt K, Englisch A, Köpke MB, Krückel A, Link T, Müller A, Reinhardt K, Roth J, Schäffler H, Sych L, Tegeler CM, Wichmann C, Banys-Paluchowski M, Princk H, Rody A, Brucker SY, Ditsch N, Ettl J, Fehm T, Hack CC, Hadji P, Hein A, Janni WW, Kolberg HC, Lüftner D, Lux MP, Müller V, Schneeweiss A, Taran FA, Tesch H, Wallwiener D, Marmé F, Seitz S, Belleville E, Hartkopf A, Michel LL, Wallwiener M, Fasching PA, Tauber N.   +51 more
europepmc   +1 more source

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy. [PDF]

Oncologist
Dai S, Wen Y, Wu X, Wang X, Yuan Z, Xu F, Xie X, Xia W, Wang S, Shi Y, Liu P, Zheng Q, Tang J, An X, Huang J, Chen M, Zhong Y, Bi X, Yang Y, Xue C.   +19 more
europepmc   +1 more source

Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States. [PDF]

Breast
Mahtani R, Korytowsky B, Rose CG, Jakobsson M, Cappelleri J, Lewis K, Lambert A, Hammond C, Criscitiello C.   +8 more
europepmc   +1 more source

Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer. [PDF]

Breast Cancer Res
Lei L, Bhave M, Kalinsky K, Gandhi S.
europepmc   +1 more source

Selective oestrogen receptor modulators and Alzheimer´s disease: a real-world pharmacovigilance study. [PDF]

Eur J Clin Pharmacol
Yuste MT, Badillo E, Galecio JS, Marín P.   +3 more
europepmc   +1 more source

Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation. [PDF]

Mol Cancer Ther
Wang H, Luo Y, Artham S, Wang Q, Peng Y, Yun Z, Li X, Wu C, Liu Z, Weber-Bonk KL, Pai CP, Cao Y, Yue J, Park S, Keri RA, Geng L, McDonnell DP, Kao HY, Yang S.   +18 more
europepmc   +1 more source

Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR⁺/HER2^-advanced breast cancer. [PDF]

Breast
Zhu J, Ding Y, Li Z, Liu W.
europepmc   +1 more source

Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS). [PDF]

Sci Rep
Kang Y, Sun X, Dang DS, Yuan Y.
europepmc   +1 more source

Sexual dimorphism in keratoconus: transcriptomic and hormonal mechanisms underlying stromal remodelling. [PDF]

Eye Vis (Lond)
Sun Y, Li Q, Wu X, Yu X, Wang R, Sun B, Wang K, Yu Y, Chen S, Jiang D, Chen W.   +10 more
europepmc   +1 more source

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. [PDF]

Nat Commun
Luo L, Wang Y, Bui T, Jiang X, Chen MK, Rao X, Mohammadhosseinpour S, Li M, Kim S, Kim RY, Kamaliasl S, Ulizio CW, Tsavachidis S, Navarro-Yepes J, Kettner NM, Wingate H, Meric-Bernstam F, Hunt KK, Wang J, Faia K, Keyomarsi K.   +20 more
europepmc   +1 more source